European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines
JA Witjes, HM Bruins, R Cathomas, EM Compérat… - European urology, 2021 - Elsevier
Context This overview presents the updated European Association of Urology (EAU)
guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). Objective To …
guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). Objective To …
European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines
JA Witjes, HM Bruins, A Carrión, R Cathomas… - European urology, 2024 - Elsevier
Context We present an overview of the updated 2023 European Association of Urology
(EAU) guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). Objective To …
(EAU) guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). Objective To …
Molecular and histopathology directed therapy for advanced bladder cancer
C Alifrangis, U McGovern, A Freeman, T Powles… - Nature Reviews …, 2019 - nature.com
Bladder cancer is a heterogeneous group of tumours with at least 40 histological subgroups.
Patients with localized disease can be cured with surgical resection or radiotherapy, but …
Patients with localized disease can be cured with surgical resection or radiotherapy, but …
Clinical applications and anticancer effects of antimicrobial peptides: from bench to bedside
Cancer is a multifaceted global health issue and one of the leading causes of death
worldwide. In recent years, medical science has achieved great advances in the diagnosis …
worldwide. In recent years, medical science has achieved great advances in the diagnosis …
Defining cisplatin eligibility in patients with muscle-invasive bladder cancer
DM Jiang, S Gupta, A Kitchlu, A Meraz-Munoz… - Nature Reviews …, 2021 - nature.com
The current treatment paradigm for muscle-invasive bladder cancer (MIBC) consists of
cisplatin-based neoadjuvant chemotherapy followed by local definitive therapy, or local …
cisplatin-based neoadjuvant chemotherapy followed by local definitive therapy, or local …
ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer
G Sonpavde, A Necchi, S Gupta, GD Steinberg… - Future …, 2020 - Taylor & Francis
Immune checkpoint inhibitors have revolutionized the treatment of patients with metastatic
urothelial carcinoma. In cisplatin-eligible muscle-invasive bladder cancer (MIBC), cisplatin …
urothelial carcinoma. In cisplatin-eligible muscle-invasive bladder cancer (MIBC), cisplatin …
Systemic immune-inflammation index is a promising non-invasive biomarker for predicting the survival of urinary system cancers: a systematic review and meta …
X Li, L Gu, Y Chen, Y Chong, X Wang, P Guo… - Annals of …, 2021 - Taylor & Francis
Objective Systemic immune-inflammation index (SII) has been reported in numerous studies
to effectively predict the survival outcomes of urinary system cancers; however no …
to effectively predict the survival outcomes of urinary system cancers; however no …
[HTML][HTML] Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆
Background Initial studies of preoperative checkpoint inhibition before radical cystectomy
(RC) have shown promising pathologic complete responses. We aimed to analyze the …
(RC) have shown promising pathologic complete responses. We aimed to analyze the …
Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients
ARAH Hamid, FR Ridwan, D Parikesit, F Widia… - BMC urology, 2020 - Springer
Background Most patients with muscle-invasive bladder cancer (MIBC) developed
metastasis within 2 years, even after radical cystectomy (RC). The recurrence rate of MIBC …
metastasis within 2 years, even after radical cystectomy (RC). The recurrence rate of MIBC …
PD‑1/PD‑L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors
Q Tang, S Zhao, N Zhou, J He… - International …, 2023 - spandidos-publications.com
A comprehensive search regarding programmed cell death protein 1 (PD‑1)/programmed
death‑ligand 1 (PD‑L1) inhibitor monotherapy or combination therapy in neoadjuvant …
death‑ligand 1 (PD‑L1) inhibitor monotherapy or combination therapy in neoadjuvant …